Holen Sie sich die Stockscreener-App
2.63
10.97%
0.26
Handel nachbörslich:
2.60
-0.03
-1.14%
Schlusskurs vom Vortag:
$2.37
Offen:
$2.35
24-Stunden-Volumen:
5.81M
Relative Volume:
0.96
Marktkapitalisierung:
$243.87M
Einnahmen:
-
Nettoeinkommen (Verlust:
$-69.31M
KGV:
-2.0709
EPS:
-1.27
Netto-Cashflow:
$-62.80M
1W Leistung:
+21.48%
1M Leistung:
-73.30%
6M Leistung:
-50.19%
1J Leistung:
-49.52%
1-Tages-Spanne:
$2.25
$2.70
1-Wochen-Bereich:
$1.87
$2.70
52-Wochen-Spanne:
$1.07
$11.46
Rezolute Inc Stock (RZLT) Company Profile
Firmenname
Rezolute Inc
Sektor
Branche
Telefon
650-206-4507
Adresse
275 SHORELINE DRIVE, SUITE 500, REDWOOD CITY
Vergleichen Sie RZLT mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
RZLT
Rezolute Inc
|
2.63 | 219.76M | 0 | -69.31M | -62.80M | -1.27 |
|
VRTX
Vertex Pharmaceuticals Inc
|
463.86 | 119.17B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
796.55 | 84.19B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
398.29 | 52.77B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ARGX
Argen X Se Adr
|
788.49 | 48.98B | 3.06B | 1.28B | 447.35M | 19.67 |
|
INSM
Insmed Inc
|
175.97 | 36.31B | 447.02M | -1.18B | -906.14M | -6.1812 |
Rezolute Inc Stock (RZLT) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-12-11 | Herabstufung | Cantor Fitzgerald | Overweight → Neutral |
| 2025-12-11 | Herabstufung | Craig Hallum | Buy → Hold |
| 2025-12-11 | Herabstufung | Wedbush | Outperform → Neutral |
| 2024-11-05 | Eingeleitet | Wedbush | Outperform |
| 2024-08-27 | Eingeleitet | Guggenheim | Buy |
| 2024-07-17 | Eingeleitet | BTIG Research | Buy |
| 2024-06-04 | Eingeleitet | Craig Hallum | Buy |
| 2024-04-09 | Eingeleitet | Maxim Group | Buy |
| 2022-08-02 | Fortgesetzt | Canaccord Genuity | Buy |
| 2022-06-15 | Eingeleitet | Cantor Fitzgerald | Overweight |
| 2021-09-08 | Eingeleitet | ROTH Capital | Buy |
| 2021-05-27 | Eingeleitet | Oppenheimer | Outperform |
| 2021-05-25 | Eingeleitet | H.C. Wainwright | Buy |
Alle ansehen
Rezolute Inc Aktie (RZLT) Neueste Nachrichten
Does Rezolute Inc. stock trade at a discount to peersAnalyst Upgrade & Long-Term Safe Return Strategies - ulpravda.ru
Will Rezolute Inc. (6HV1) stock test record highs in 2025Market Activity Report & Fast Entry Momentum Alerts - ulpravda.ru
UPCOMING DEADLINE: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Rezolute - Bluefield Daily Telegraph
Rezolute (RZLT): Wedbush Analyst Raises Price Target to $2.00 | RZLT Stock News - GuruFocus
Why analysts upgrade Rezolute Inc. stockJuly 2025 Macro Moves & Free Fast Entry Momentum Trade Alerts - ulpravda.ru
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Rezolute, Inc.RZLT - Chartmill
Jefferies reiterates Buy rating on Rezolute stock, maintains $4 target By Investing.com - Investing.com Canada
Wedbush Doubles Price Target on Rezolute to $2 From $1, Keeps Neutral Rating - MarketScreener
BTIG Reiterates Buy Rating for Rezolute (RZLT) with $5 Target Pr - GuruFocus
Rezolute Hopes To Find A Way Forward In Congenital HI After Phase III Miss - Citeline News & Insights
Rezolute (RZLT) Shows Promising Results in Hypoglycemia Treatmen - GuruFocus
Can Rezolute's SunRIZE Study, Tumor HI Data Redefine Treatment For Hyperinsulinism? - Nasdaq
Rezolute (RZLT) Analyzes Phase 3 sunRIZE Study Outcomes - GuruFocus
Rezolute shares mixed results from Phase 3 trial for rare disease therapy - Investing.com Nigeria
Rezolute rises as drug shows promise for rare low blood sugar disorders - TradingView — Track All Markets
Rezolute, Inc. Shares Findings on Ersodetug's Efficacy for Congenital and Tumor Hyperinsulinism, Plans FDA Meeting to Discuss Path Forward - Quiver Quantitative
Rezolute Provides Insights from its Phase 3 sunRIZE Study in Congenital Hyperinsulinism and Shares Findings from its Expanded Access Program in Tumor Hyperinsulinism - The Manila Times
Experimental drug lets some severe hypoglycemia patients leave IV sugar behind - Stock Titan
Rezolute Updates sunRIZE Phase 3 Trial and FDA Plans - TipRanks
Rezolute, Inc. Provides Insights from sunRIZE Study and EAP - TradingView — Track All Markets
Potential Securities Fraud: Levi & Korsinsky Investigates Rezolute, Inc. (RZLT) - ACCESS Newswire
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Rezolute, Inc. ... - Bluefield Daily Telegraph
INVESTOR ALERT: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Rezolute - PR Newswire
Rezolute, Inc. (NASDAQ:RZLT) Given Consensus Recommendation of "Hold" by Brokerages - MarketBeat
ATTENTION Rezolute, Inc. (RZLT) Investors: Possible FraudContact Levi & Korsinsky Today - ACCESS Newswire
INVESTIGATION REMINDER: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of RZLT - FinancialContent
Rezolute’s Phase 3 SunRIZE study for Ersodetug fails to meet primary and secondary endpoints despite analyst backing - MSN
Shareholders Alert: Investigation Into Rezolute, Inc. (RZLT) – Contact Levi & Korsinsky to Protect Your Rights - ACCESS Newswire
Investigation Underway: Rezolute, Inc. (RZLT)Contact Levi & Korsinsky Over Securities Law Violations - ACCESS Newswire
Weekly Trades: Will Rezolute Inc 6HV1 stock test record highs in 20252025 Historical Comparison & Free AI Powered Buy and Sell Recommendations - moha.gov.vn
Rezolute shares in focus after RA Capital discloses 9.9% stake - MSN
Revenue per share of Rezolute, Inc. – FWB:6HV1 - TradingView — Track All Markets
Investors in Rezolute, Inc. (RZLT) Warned of Potential Securities FraudContact Levi & Korsinsky Today - ACCESS Newswire
Levi & Korsinsky Investigates Rezolute, Inc. (RZLT) Over Potential Securities Fraud Allegations - ACCESS Newswire
Rezolute's Phase 3 sunRIZE Study for Ersodetug Fails to Meet Primary and Secondary Endpoints Despite Analyst Backing - Finviz
INVESTIGATION: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of RZLT - The Malaysian Reserve
Rezolute’s Phase 3 sunRIZE Study for Ersodetug Fails to Meet Primary and Secondary Endpoints Despite Analyst Backing - Insider Monkey
Rezolute Faces Legal Scrutiny Following Disastrous Clinical Trial Results - timothysykes.com
Rezolute, Inc. (RZLT) Shares Tank 90% Amid Lead Asset Trial Fail - GuruFocus
Lost Money on Rezolute, Inc. (RZLT)? Possible FraudContact Levi & Korsinsky Today - ACCESS Newswire
Rezolute Faces Investor Outrage Amid Legal Scrutiny Following Trial Setback - StocksToTrade
About Us | Oil & Gas JournalRezolute, Inc.Common Stock (NV) (Nasdaq:RZLT) Stock Quote - FinancialContent
Investigation Alert: Levi & Korsinsky Investigates Securities Fraud Claims Against Rezolute, Inc. (RZLT) - ACCESS Newswire
Rezolute, Inc. (RZLT) Shares Tank 90% Amid Lead Asset Trial Failure -- Hagens Berman Investigating - PR Newswire
Ongoing Rezolute, Inc. (RZLT) Investigation: Protect Your Rights – Contact Levi & Korsinsky - ACCESS Newswire
Rezolute Stock: A Deluge of Turmoil - StocksToTrade
RZLT ALERT: Levi & Korsinsky Investigates Rezolute, Inc. for Possible Securities Fraud Violations - ACCESS Newswire
Ongoing Investigation: Rezolute, Inc. (RZLT) May Have Misled Shareholders – Levi & Korsinsky Investigates - ACCESS Newswire
INVESTIGATION ALERT: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Rezolute - TMX Newsfile
Rezolute downgraded to neutral from overweight at Cantor Fitzgerald - MSN
Investigation Opened on Behalf of Rezolute, Inc. (RZLT) ShareholdersContact Levi & Korsinsky - ACCESS Newswire
Finanzdaten der Rezolute Inc-Aktie (RZLT)
Umsatz
Nettogewinn
Free Cashflow
ENV
0.90%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):